ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX) today announced that it will host a conference call on Thursday, March 31, to update investors on the Company’s recent accomplishments and objectives for the remainder of 2016. Among the highlights of the call will be an update on the clinical trials currently underway for Renevia® for lipoatrophy, and OpRegen® for dry age-related macular degeneration. In addition, management will discuss recent developments for its other clinical stage programs: AST-VAC1 cancer immunotherapy for acute myeloid leukemia, AST-OPC1 for spinal cord injury, and OncoCyte’s diagnostic programs in oncology. BioTime will also review recent corporate transactions and collaborations.
